ATRC Share Price

Open 21.17 Change Price %
High 21.54 1 Day 0.39 1.85
Low 20.86 1 Week 0.00 0.00
Close 21.44 1 Month -0.84 -3.77
Volume 246022 1 Year 1.49 7.47
52 Week High 25.18
52 Week Low 14.78
ATRC Important Levels
Resistance 2 22.07
Resistance 1 21.81
Pivot 21.28
Support 1 21.07
Support 2 20.81
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%

AtriCure, Inc. (NASDAQ: ATRC)

ATRC Technical Analysis 1.5
As on 31st Oct 2017 ATRC Share Price closed @ 21.44 and we RECOMMEND Buy for LONG-TERM with Stoploss of 20.49 & Sell for SHORT-TERM with Stoploss of 21.97 we also expect STOCK to react on Following IMPORTANT LEVELS.
ATRC Target for May
1st Target up-side 23.02
2nd Target up-side 24.12
3rd Target up-side 25.22
1st Target down-side 19.86
2nd Target down-side 18.76
3rd Target down-side 17.66
ATRC Other Details
Segment EQ
Market Capital 121395064.00
Sector Healthcare
Industry Medical Instruments & Supplies
Offical website
ATRC Address
6217 Centre Park Drive
West Chester, OH 45069
United States
Phone: 513-755-4100
ATRC Latest News
Interactive Technical Analysis Chart AtriCure, Inc. ( ATRC NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on AtriCure, Inc.
ATRC Business Profile
AtriCure, Inc., incorporated on October 31, 2000, is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage. The Company has two primary product lines for the ablation of cardiac tissue. Its primary product line, which accounts for a majority of its revenues is the AtriCure Synergy Ablation System, a bipolar ablation clamp system and related radiofrequency ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. In addition, it offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System, or AtriClip system, which is designed to exclude the left atrial appendage. In January 2014, the Company announced that it has completed the acquisition of Endoscopic Technologies, Inc. d/b/a Estech. In the United States, the Company primarily sells its products to medical centers through its direct sales force. AtriCure Europe, B.V., its wholly owned subsidiary, markets and sells its products throughout Europe, the Middle East and Africa (EMEA) primarily through distributors, while in Germany and Benelux region the Company sells directly to medical centers. The Company sells its products to other international distributors, primarily in Asia, South America and Canada. The Company’s synergy System and related radio-frequency ( RF) devices such as its multifunctional pens represent its primary product line. Its Synergy System and related RF devices are used in both open and minimally invasive procedures. The Company’s products include Isolator Synergy Bipolar Radio-Frequency Ablation Clamps, Ablation and Sensing Unit (ASU), AtriCure Switch Box (ASB) and Isolator Multifunctional Pens. The Company sells multiple configurations of its Isolator Synergy clamps. During the year ended December 31, 2011, the Company released its Isolator Synergy Access clamps in the United States, a new open-heart configuration featuring a pivoting clamp head. Its Isolator Synergy clamps are single-use disposables and have jaws that close in a parallel fashion.